Price alert —
Sign in to get a one-time email the moment DBVT crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · DBVT
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | — | $-0.1B | $-0.1B | $-0.1B | — | — |
| 2026-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-12-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-09-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-06-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-03-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare DBVT vs peers
Line DBVT up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
DBVT
DBV Technologies S.A.
$14.70
-1.08%
META
Meta Platforms, Inc.
$646.01
-2.79%
AAPL
Apple Inc.
$333.74
+0.14%
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-07-16 | -0.10 | -0.09 | -12.0% | -1.1% |
| 2026-04-30 | -0.09 | -0.12 | +22.5% | -5.4% |
| 2026-03-26 | -0.20 | -0.19 | -5.7% | -1.0% |
| 2025-10-28 | -0.21 | -0.29 | +29.4% | -2.2% |
| 2025-07-29 | -0.27 | -0.16 | -71.6% | -4.1% |
| 2025-04-30 | -0.23 | -0.22 | -3.2% | -4.4% |
| 2025-03-24 | -0.21 | -0.21 | -1.3% | -10.1% |
| 2024-11-06 | -1.49 | -1.64 | +9.2% | -4.0% |
| 2024-07-30 | -1.57 | -2.65 | +40.6% | +2.3% |
| 2024-05-07 | -5.20 | -2.06 | -152.8% | +2.1% |
| 2024-03-07 | -2.01 | -2.43 | +17.3% | +3.9% |
| 2023-10-31 | -1.61 | -2.63 | +38.8% | +1.0% |
| 2023-07-31 | -2.36 | -2.27 | -3.9% | +8.8% |
| 2023-05-04 | -2.00 | -2.36 | +15.3% | +5.8% |
| 2023-03-02 | -8.49 | -1.71 | -395.4% | +5.1% |
| 2022-11-03 | -3.69 | -3.15 | -17.1% | -1.3% |
| 2022-08-01 | -3.41 | -3.03 | -12.6% | -4.0% |
| 2022-05-02 | -2.86 | -4.34 | +34.2% | -8.3% |
| 2022-03-08 | -3.79 | -8.95 | +57.6% | +5.3% |
| 2022-03-03 | -12.68 | -4.25 | -198.4% | -23.4% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| DBVT ★ | $1B | — | -27.9 | 172.8 | -4.0 | 4.2 | 100.0% | -53.3% | — | -12.05% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | — | 30.0 | — | — | — | — | — | 9.9% | — | 2.01% |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 29.04%
| Holder | Shares | % out |
|---|---|---|
| MPM Bioimpact LLC | 5,213,361 | 8.80% |
| Vivo Capital, LLC | 2,667,569 | 4.51% |
| Artisan Partners Limited Partnership | 2,219,386 | 3.75% |
| Siren, L.L.C. | 1,857,362 | 3.14% |
| Baker Bros. Advisors, LP | 1,461,425 | 2.47% |
| Adar1 Capital Management, LLC | 1,012,866 | 1.71% |
| Perceptive Advisors Llc | 964,391 | 1.63% |
| Patient Square Capital LP | 693,534 | 1.17% |
| Octagon Capital Advisors LP | 574,200 | 0.97% |
| Ikarian Capital, LLC | 525,000 | 0.89% |
Insider activity · 90d
No insider trades for DBVT in last 90d.
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-07-16 | 8-K | view · |
| 10-Q | 2026-07-16 | 10-Q | view · |
| 8-K | 2026-06-29 | 8-K | view · |
| 8-K | 2026-06-05 | 8-K | view · |
| 8-K | 2026-06-03 | 8-K | view · |
| DEF 14A | 2026-05-11 | DEF 14A | view · |
| 8-K | 2026-05-05 | 8-K | view · |
| 8-K | 2026-04-30 | 8-K | view · |
| 10-Q | 2026-04-30 | 10-Q | view · |
| 8-K | 2026-03-26 | 8-K | view · |
| 10-K | 2026-03-26 | 10-K | view · |
| 8-K | 2026-03-02 | 8-K | view · |
| 4 | 2026-02-02 | Insider transaction (Form 4) | view · |
| 8-K | 2026-01-20 | 8-K | view · |
| 4 | 2026-01-14 | 4 | view · |
| 4 | 2025-12-19 | OWNERSHIP DOCUMENT | view · |
| 8-K | 2025-12-16 | 8-K | view · |
| 4 | 2025-11-25 | Insider transaction (Form 4) | view · |
| 4 | 2025-11-24 | Insider transaction (Form 4) | view · |
| 4 | 2025-11-24 | Insider transaction (Form 4) | view · |
| 4 | 2025-11-24 | Insider transaction (Form 4) | view · |
| 8-K | 2025-10-30 | 8-K | view · |
| 8-K | 2025-10-29 | 8-K | view · |
| 10-Q | 2025-10-28 | 10-Q | view · |
| 8-K | 2025-09-18 | 8-K | view · |
| 8-K | 2025-09-05 | 8-K | view · |
| 4 | 2025-07-31 | Insider transaction (Form 4) | view · |
| 8-K | 2025-07-29 | 8-K | view · |
| 10-Q | 2025-07-29 | 10-Q | view · |
| 8-K | 2025-06-25 | 8-K | view · |
| 8-K | 2025-06-11 | 8-K | view · |
| 4 | 2025-05-27 | Insider transaction (Form 4) | view · |
| DEF 14A | 2025-05-15 | DEF 14A | view · |
| 8-K | 2025-04-30 | 8-K | view · |
| 10-Q | 2025-04-30 | 10-Q | view · |
| 10-K | 2025-04-11 | 10-K | view · |
| 4 | 2025-03-31 | 4 | view · |
| 8-K | 2025-03-31 | 8-K | view · |
| 8-K | 2025-03-24 | 8-K | view · |
| 4 | 2025-01-31 | Insider transaction (Form 4) | view · |
| 8-K | 2025-01-08 | 8-K | view · |
| 8-K | 2024-12-18 | 8-K | view · |
| 8-K | 2024-12-16 | 8-K | view · |
| 8-K | 2024-12-11 | 8-K | view · |
| 4 | 2024-12-05 | Insider transaction (Form 4) | view · |
| 4 | 2024-11-27 | Insider transaction (Form 4) | view · |
| 4 | 2024-11-25 | Insider transaction (Form 4) | view · |
| 4 | 2024-11-25 | Insider transaction (Form 4) | view · |
| 8-K | 2024-11-12 | 8-K | view · |
| 8-K | 2024-11-06 | 8-K | view · |
| 10-Q | 2024-11-06 | 10-Q | view · |
| 8-K | 2024-10-22 | 8-K | view · |
| 8-K | 2024-09-23 | 8-K | view · |
| 4 | 2024-07-31 | Insider transaction (Form 4) | view · |
| 8-K | 2024-07-30 | 8-K | view · |
| 10-Q | 2024-07-30 | 10-Q | view · |
| 8-K | 2024-06-18 | 8-K | view · |
| 8-K | 2024-05-31 | 8-K | view · |
| 4 | 2024-05-29 | Insider transaction (Form 4) | view · |
| 8-K | 2024-05-17 | 8-K | view · |
About DBVT
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Options picks · DBVT
ITM + OTM ideas from the latest scanLoading…
Congress trades · DBVT
STOCK Act disclosuresLoading…
SEC filings & insiders · DBVT
EDGAR · liveLoading…
Holders · DBVT
Institutions & insider activityLoading…